Does Urolithin A Slow Aging?
A careful look at the human evidence behind the mitochondrial health and healthy-aging supplement claim.
Urolithin A may help selected muscle fatigue or strength tests, but human evidence has not shown slower aging, longer life, disease prevention, or consistent everyday physical benefit.
Urolithin A is biologically interesting, but not a proven anti-aging supplement. Small human trials show possible benefits in selected muscle-strength or fatigue-resistance tests. Broader outcomes, including walking ability, muscle mass, aerobic performance and whole-body physical function, have been inconsistent or negative.
There is no reliable human evidence that urolithin A slows aging, extends life, prevents dementia, or protects people from age-related disease.
The claim
“Urolithin A supplements improve mitochondrial health, muscle function, and healthy aging.”
This is a broad claim, so WEH separates the biological mechanism from the outcomes people actually care about. A supplement can change a lab marker or a cellular pathway without proving that people walk farther, stay independent, avoid disease, or live longer.
At a glance
What is urolithin A?
Urolithin A is a compound that some gut bacteria can make after we eat foods containing ellagitannins and ellagic acid. These plant compounds are found in foods such as pomegranates, berries and walnuts. The amount produced varies because people have different gut bacteria.
Commercial supplements generally contain a manufactured version of urolithin A rather than an extract of the original fruit. The Australian Therapeutic Goods Administration describes the supplement ingredient as a synthetic version of the compound formed in the body after ellagitannins and ellagic acid are consumed [9].
Why is it marketed for healthy aging?
Urolithin A is thought to stimulate mitophagy. Mitophagy is the process cells use to identify, remove and recycle damaged mitochondria, the structures that help cells release usable energy from food.
What does the overall evidence say?
A 2024 systematic review identified five studies involving 250 healthy participants. It reported possible improvements in muscle strength, muscle endurance, inflammatory markers and selected mitochondrial pathways, but no clear benefit for physical function, body measurements or cardiovascular outcomes [1].
A 2025 systematic review preprint focused on muscle strength, muscle mass and physical performance. It included three randomised trials with 174 participants. Only four of 12 measured outcomes showed a statistically significant benefit. The pooled six-minute-walk result was not significant, and the only study measuring muscle mass found no benefit [2].
Claim-by-claim findings
Open each item for the evidence logic behind the verdict.
Possible, weak
Selected muscle fatigue and strength tests may improve
Evidence: small human RCTs, mixed outcomes
v
The ENERGIZE trial in 66 adults aged 65 to 90 found no significant improvement in six-minute walking distance or maximal muscle energy production compared with placebo, but some repeated-contraction fatigue tests improved at two months [3]. The ATLAS trial in 88 middle-aged adults found improved hamstring strength, but the primary peak-power outcome did not significantly improve [4].
Inconsistent
Walking ability, muscle mass and physical function remain unproven
Evidence: mixed trial results and limited pooled data
v
The strongest practical outcomes are not consistently positive. Six-minute walking distance did not significantly improve in the ENERGIZE trial, between-group differences in six-minute walking distance did not reach statistical significance in ATLAS, and the 2025 preprint meta-analysis found no statistically significant pooled six-minute-walk benefit [3] [4] [2].
Not supported
Slower aging, longer life and disease prevention are not shown
Evidence: no direct human longevity or disease-prevention trials
v
No completed human trial has shown that urolithin A extends lifespan, slows an accepted clinical measure of aging, prevents frailty, prevents dementia, reduces cardiovascular disease or cancer, reduces hospitalisation, or lowers disability.
Biological effect
Immune and inflammation markers are not the same as health outcomes
Evidence: short biomarker trials
v
A 2025 trial in 50 healthy middle-aged adults found changes in some immune-cell populations and measures of mitochondrial activity. This suggests biological activity, but it did not show fewer infections, better vaccine response, less cancer, or another direct health improvement [8].
Uncertain
Long-term safety is not well established
Evidence: short trials in selected populations
v
Urolithin A was generally well tolerated in short human trials, with adverse events usually mild or moderate and no consistent difference between urolithin A and placebo in the review evidence [1].
- Human evidence includes randomised placebo-controlled trials, but most are small and short.
- Positive results are not consistent across strength, walking, aerobic performance, muscle mass and whole-body function.
- Several positive findings are secondary or exploratory outcomes rather than the main trial outcome.
- No human trial shows slower aging, longer life, or prevention of age-related disease.
- Independent replication matters because several key studies report manufacturer funding or conflicts.
Evidence summary table
For readers who want to inspect the main studies behind the verdict.
| Citation / N | Key result | Risk of bias / limits |
|---|---|---|
| Kuerec et al. 2024 Systematic review; five studies, 250 healthy adults |
Possible benefits in selected strength, endurance and biological markers; no clear physical-function benefit. | Few small, short studies; mixed outcomes. |
| Watts et al. 2025 Systematic review preprint; three RCTs, 174 participants |
Four of 12 outcomes positive; walking-distance result not significant; no muscle-mass benefit. | Preprint, not peer reviewed; limited number of trials. |
| Liu et al. 2022 Randomised placebo-controlled trial; 66 older adults |
Some fatigue-resistance tests improved; walking and maximal muscle energy production did not. | Small trial; secondary findings; manufacturer funding and conflicts. |
| Singh et al. 2022 Randomised placebo-controlled trial; 88 middle-aged adults |
Hamstring strength improved; primary peak-power outcome did not. | Proof-of-concept study; multiple outcomes; manufacturer funding and conflicts. |
| Zhao et al. 2024 Randomised placebo-controlled trial; 20 resistance-trained men |
Some isometric strength and fatigue results improved. | Very small, male-only study; conventional strength measures not significant. |
| Whitfield et al. 2025 Randomised placebo-controlled trial; 36 trained male runners |
Some recovery-related changes; no improvement in running performance. | Short, male-only study; company involvement. |
| Monsalve Acevedo et al. 2025 Pilot randomised trial; 20 male academy soccer players |
Reported improvements in some aerobic and jumping measures. | Very small pilot trial; short duration; confirmation needed. |
| Denk et al. 2025 Randomised placebo-controlled trial; 50 healthy adults |
Changes in immune-cell and mitochondrial measurements. | No direct health outcomes; short duration; company funding and conflicts. |
What this means for you
Practical takeaway
If your goal is a proven anti-aging strategy, urolithin A is not there yet.
If your goal is muscle function, the best current evidence suggests possible small benefits in selected tests, not a reliable improvement in everyday performance.
- Treat urolithin A as preliminary, not proven.
- Be skeptical of lifespan, “mitochondrial rejuvenation” or disease-prevention claims.
- Do not confuse mechanism, animal data or biomarker changes with demonstrated human health benefit.
- Look for larger, longer and independently funded human trials before taking strong claims seriously.
FAQ
Short answers to the most common questions about urolithin A supplements.
Does urolithin A slow aging?
v
Not based on current human evidence. Human trials have not shown that urolithin A extends lifespan, slows an accepted clinical measure of aging, prevents frailty, or prevents age-related disease. Most studies are short and focus on muscle tests or biological markers rather than long-term health outcomes [1] [2].
Does it improve muscle strength or endurance?
v
Is taking urolithin A the same as eating pomegranate, berries or walnuts?
v
No. Some gut bacteria can make urolithin A after people eat foods containing ellagitannins and ellagic acid, but production varies between people. Commercial supplements generally contain a manufactured version of urolithin A rather than the original fruit compound [9].
Is urolithin A safe?
v
It was generally well tolerated in short human trials, but that is not the same as proven long-term safety. Long-term daily use, uncommon adverse effects, medicine interactions, and safety during pregnancy, breastfeeding and childhood are not well established [1].
What evidence would make WEH more confident?
v
The claim would need larger, longer, independently funded human trials showing meaningful outcomes such as better everyday physical function, reduced frailty, less disability, fewer age-related diseases, or longer survival. Biomarkers and plausible mechanisms are not enough on their own.
Sources
- Kuerec AH, Lim XK, Khoo ALY, et al. Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews. 2024;100:102406. PubMed.
- Watts P, McDonald C, Sayer AA, Witham MD. The effects of urolithin A supplementation on muscle strength, muscle mass and physical performance in humans: a systematic review. medRxiv. 2025. Preprint.
- Liu S, D’Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2144279. PubMed.
- Singh A, D’Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633. PubMed.
- Zhao H, Zhu H, Yun H, et al. Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study. Journal of the International Society of Sports Nutrition. 2024;21(1):2419388. PubMed.
- Whitfield J, McKay AKA, Tee N, et al. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. Sports Medicine. 2025;55:3183-3200. PubMed.
- Monsalve Acevedo A, Sanctuary C, Aitken RJ, et al. Effects of Urolithin A supplementation on performance and antioxidant status in academy soccer players during preseason: a pilot randomised controlled trial. Frontiers in Nutrition. 2025;12:1674446. PubMed.
- Denk D, Singh A, Kasler HG, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025;5:2309-2322. Full text.
- Therapeutic Goods Administration. Urolithin A: compositional guideline for use in listed medicines. Updated 1 October 2025. TGA guideline.
